DiaMedica Therapeutics Inc. DMAC

DMAC Company Overview

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for severe ischemic diseases, with primary emphasis on acute ischemic stroke and preeclampsia. The company operates within the biotechnology and specialty pharmaceutical industries and is publicly traded on the Nasdaq under the ticker DMAC. DiaMedica’s lead product candidate is DM199, a recombinant form of human tissue kallikrein-1 (rhKLK1), which is designed to enhance microvascular blood flow, reduce inflammation, and promote tissue repair. The company’s business model is centered on advancing proprietary biologic therapies through clinical development and regulatory approval processes.

The company was founded in Canada in 2000 and later established U.S.-focused operations as its clinical programs expanded. DiaMedica evolved from earlier-stage neurological and kidney disease research into a more concentrated strategy targeting ischemic vascular conditions. Its positioning is largely tied to the potential differentiation of DM199 as a mechanism-based biologic therapy intended to address unmet medical needs in stroke care and vascular dysfunction, particularly in areas where current standard-of-care treatments are limited by timing windows or contraindications.